NCT00226473

Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma

Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (planned)
• Sponsor: Dermatologic Cooperative Oncology Group · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this multicenter study is to examine whether the proposed randomized treatment regime results in a significantly longer survival time and higher quality of life than any additionally applied multiple chemotherapy according to the CVD- scheme. So far neither established treatment regimes nor reliable data exist for the second-line chemotherapy of metastatic malignant melanoma. Patients are therefore mostly treated with single or multiple chemotherapeutics or/and immunomodulatory therapeutics. These regimes however imply often not only a higher toxicity but show rarely a response rate higher than 10%.

Conditions

• Metastatic Melanoma

Interventions

Type	Name	Description
DRUG	Cisplatin, Vindesine, Dacarbazine (drugs)

Timeline

• Start date: 2001-09-01
• Completion: 2005-09-01
• First posted: 2005-09-27
• Last updated: 2006-06-21

Locations

13 sites across 1 country: Germany